Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
ACS Chemical Neuroscience February 20, 2018 DOI: 10.1021/acschemneuro.8b00043 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Addiction Anxiety LSD Psilocybin |
| Keywords | Hallucinogen Neurochemistry Psychopharmacology |
| Citations | 87 |
| Key findings | LSD is a potent, physiologically safe, nonaddictive psychoactive agent that ended clinical research in the 1970s but has recently resumed in Europe, with promising therapeutic results in small pilot trials using psilocybin for depression, anxiety, and addictions. |
Abstract
Lysergic acid diethylamide (LSD) is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 μg) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led to ideas that serotonin in the brain might be involved in mental disorders, initiating rapid research interest in the neurochemistry of serotonin. LSD proved to be physiologically very safe and nonaddictive, with a very low incidence of adverse events when used in controlled experiments. Widely hailed by psychiatry as a breakthrough in the 1950s and early 1960s, clinical research with LSD ended by about 1970, when it was formally placed into Schedule 1 of the Controlled Substances Act of 1970 following its growing popularity as a recreational drug. Within the past 5 years, clinical research with LSD has begun in Europe, but there has been none in the United States. LSD is proving to be a powerful tool to help understand brain dynamics when combined with modern brain imaging methods. It remains to be seen whether therapeutic value for LSD can be confirmed in controlled clinical trials, but promising results have been obtained in small pilot trials of depression, anxiety, and addictions using psilocybin, a related psychedelic molecule.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Notes LSD is physiologically safe and nonaddictive and that promising results have been obtained in small pilot trials of psychedelics for addictions, while controlled confirmation is pending.
Synthesized
Comparable studies
Other narrative reviews on LSD for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Psychedelic Drugs in Biomedicine | 2017 | Review | |
| The Past and Future of Psychedelic Science: An Introduction to This Issue | 2019 | Review | |
| Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders | 2022 | Review | |
| Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin | 2013 | Review |
Citations in the library
Cited by 50
- Global Street Food: la cocina de la calle Diseño interior 2009
- Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects Neuropsychopharmacology October 15, 2020
- The History of Psychedelics in Psychiatry Pharmacopsychiatry December 7, 2020
- Therapeutic effect of psilocybin in addiction: A systematic review Frontiers in Psychiatry February 9, 2023
- Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD) Drug Testing and Analysis May 13, 2019
and 45 more in the library
Cites 59
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences April 11, 2016
- Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases The Journal of Nervous and Mental Disease March 4, 2014
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology March 8, 2012
- Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Current Biology April 13, 2016
and 54 more in the library